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Abstract 
Background: A rapid diagnostic tool is being developed to discern severely ill children with severe malaria from 
children who are ill with alternative febrile diseases but have coincidental peripheral blood parasitaemia. The device 
semi-quantitatively measures plasma pfHRP2 and has the potential to reduce mortality in children with severe febrile 
illnesses by improving diagnosis. The aim of this study is to identify contributing and inhibiting factors that affect 
healthcare practitioners’ acceptability of this prospective diagnostic device in a high malaria transmission setting in 
the Democratic Republic of Congo.
Methods: Data were collected qualitatively by conducting semi-structured interviews with a purposeful sample 
of health professionals in Kinshasa, capital of Democratic Republic of Congo. In total, 11 interviews were held with 
professionals at four different institutes.
Results: Four key findings emerged: (1) Congolese practitioners perceive the semi-quantitative pfHRP2 device as a 
welcome intervention as they recognize the limited reliability of their current diagnostic and therapeutic approaches 
to severe febrile illnesses; (2) compatibility of the semi-quantitative pfHRP2 device with clinical equipment and com-
petences of Congolese health practitioners is considered to be limited, especially in rural settings; (3) a formal training 
programme is crucial for correct understanding and application of the semi-quantitative pfHRP2 device; and, (4) pro-
vision of evidence to practitioners, and support from health authorities would be important to establish confidence in 
the semi-quantitative pfHRP2 device.
Conclusions: Congolese practitioners perceive the prospective semi-quantitative pfHRP2 device as a welcome addi-
tion to their clinical equipment. The device could improve current diagnostic work-up of severe febrile illness, which 
might consequently improve treatment choices. However, despite this recognized potential, several hurdles and driv-
ers need to be taken into account when implementing this device in DR Congo.
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Background
It is estimated that one in every ten newborns in the sub-
Sahara African region dies before reaching the age of 
five [1]. A high burden of infectious and other childhood 
illnesses, in combination with underperforming health-
care systems, lies at the root of this alarming number. One 
major problem relates to the diagnosis of severe febrile 
illnesses. Clinical diagnosis is difficult because symptoms 
of different diseases overlap, and adequate diagnostic 
tools are frequently unavailable [2]. This problem is par-
ticularly prevalent in the context of falciparum malaria. 
Malaria is one of the major causes of child mortality in 
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sub-Saharan Africa, with an estimated 468,000 malaria 
attributed deaths under the age of 5 years in 2012 alone 
[3]. Clinical symptoms of a malaria infection are not spe-
cific and there is significant overtreatment in children 
with a clinical diagnosis of malaria [4]. Recognition of 
this problem is reflected in WHO guidelines stressing the 
importance of confirming suspected malaria either via 
microscopy or malaria rapid diagnostic test (RDT) before 
administering treatment [5]. This paradigm of evidence-
based treatment improved management of both malaria 
and non-malarial febrile illnesses in the region by ena-
bling practitioners to administer more appropriate medi-
cation with increased confidence [3].
However, correct diagnostic work-up of febrile ill 
children in medium to high falciparum malaria zones 
remains challenging. In such areas, febrile symptoms are 
often still equated with malaria, and treated accordingly, 
even when RDT results are negative [4, 6]. Another, more 
nuanced problem associated with correct malaria diag-
nosis is represented by febrile ill children who have labo-
ratory or RDT confirmed malaria, but where the malaria 
infection is not causing the febrile episode. Instead, the 
illness is concomitant to an alternative but undetected 
infection whilst presence of the malaria parasites is 
coincidental. This is frequent in high transmission areas 
where children develop immunity to Plasmodium falci-
parum parasites during the early years of life or where 
they experience an extended period of parasite positivity 
after effective treatment of a recent malaria episode [7, 
8]. These semi-immune children can tolerate parasitae-
mia, but remain asymptomatic despite carrying parasite 
burdens detectable with microscopy or RDT. Currently, 
no available reliable diagnostic method distinguishes 
between children who suffer from severe malaria and 
children with severe non-malarial febrile illness and a 
co-incidental episode of uncomplicated malaria. When 
malaria is detected in a febrile child, the health prac-
titioner will obviously begin anti-malarial treatment, 
neglecting the high a priori chance that such a child is 
parasitaemic due to background prevalence.
Research shows that up to 20  % of children present-
ing with severe febrile illness and a positive malaria slide 
have an alternative diagnosis, often in the form of inva-
sive bacterial sepsis [4, 9–13]. This causes overdiagnosis 
of malaria, whereas the non-malarial but potentially fatal 
febrile illness often remains undiscovered and untreated. 
An innovative approach to this problem relates to the 
discovery of plasma P. falciparum histidine-rich protein 
2 (pfHRP2) concentrations as a measure for total parasite 
burden, including the sequestered parasite biomass not 
detectable in the peripheral blood [14]. Plasma pfHRP2 
strongly correlates with malaria disease severity and low 
values make P. falciparum as a cause of severe disease 
unlikely as was demonstrated by research [15, 16], with 
similar findings being obtained across varying settings 
[17–20]. No other biomarker matches plasma pfHRP2 in 
this regard. Additional support for low plasma pfHRP2 as 
indicator for the high likelihood of an alternative diagno-
sis than just falciparum malaria causing the severe febrile 
illness comes from an observation made in the large tri-
als comparing parenteral artesunate with quinine for the 
treatment of severe malaria (AQUAMAT and SEAQ-
UAMAT) [21, 22]. The lower benefit of artesunate over 
quinine in African children compared to Asian adult 
patients is entirely explained by lack of additional advan-
tage in children in the lowest tertile of plasma pfHRP2 
levels, where misdiagnosis is likely [23].
Understanding of the diagnostic potential of plasma 
pfHRP2 prompted efforts to translate this approach into 
a point-of-care diagnostic device. In the current paper, 
this emerging tool will be referred to as semi-quantitative 
pfHRP2 device. The semi-quantitative pfHRP2 device 
measures plasma pfHRP2 levels and will be applicable 
to rapidly indicate the likelihood of malaria being the 
underlying cause of severe febrile illness in parasitaemic 
African children. Since direct and swift intervention is 
essential to prevent mortality in these cases, the semi-
quantitative pfHRP2 device would be particularly suitable 
for emergency management, as an additional step in the 
diagnostic work-up. The device is being developed in a 
point-of-care, lateral-flow design similar to RDT, includ-
ing a readout where coloured lines will appear according 
to thresholds in parasite concentrations. Those concen-
trations will be measured semi-quantitatively, with a high 
cut-off measure above which P. falciparum is highly likely 
the cause of the presenting severe febrile illness, requir-
ing prompt parenteral anti-malarial treatment. In addi-
tion, there will be a low cut-off measure, below which 
the episode of severe febrile illness is highly likely caused 
by an alternative diagnosis while presence of P. falcipa-
rum parasites is not causing complications. This situation 
would warrant further investigation with additional diag-
nostic assessment and alternative treatment, including 
targeted antibiotics [15, 16].
Even though the diagnostic value of plasma pfHRP2 
is promising, it is not clear whether health practition-
ers in high malaria transmission settings would embrace 
this prospective device. Important factors for successful 
adoption of—and adherence to—this diagnostic innova-
tion are the extent to which the test fits within the health-
care system and socio-behavioural needs are addressed 
[24]. This study is a first exploration aiming to identify 
relevant contributing and inhibiting factors affecting 
acceptability of the semi-quantitative pfHRP2 device by 
its intended end-users in the Democratic Republic of 
Congo (DR Congo).
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Methods
Study area
DR Congo was selected as the site of study because its 
child mortality rates and malaria prevalence are amongst 
the highest in the world [25]. This makes DR Congo an 
important target area for the semi-quantitative pfHRP2 
device. The country is located in central Africa and has 
an estimated population of 75.5 million [26]. The official 
language is French, a heritage from the Belgium coloniza-
tion period, although various other languages are being 
spoken in different districts. The capital of DR Congo, 
Kinshasa, is situated in the west and houses circa 8.6 mil-
lion people [26]. The Human Development Index ranks 
DR Congo as one of the least developed countries in the 
world with a GNI per capita of 300 USD and 80 % of the 
population living on less than 1 USD a day [27]. Congo-
lese life expectancy is 50 years, and one in seven children 
die before their fifth birthday. The estimated fraction of 
malaria in under-five mortality is 19 % [28]. Availability 
of anti-malarial medication and of diagnostic tests is con-
sidered to be high in urban areas compared to rural ones 
in DR Congo. The 2013 surveys by ACTWatch in Kin-
shasa indicate that anti-malarial medication is available 
in nearly all private and public health facilities and drug 
outlets. Chances of receiving quality-assured ACT ther-
apy is highest in Kinshasa’s public health facilities, with 
an estimated 50  %. Diagnostic tests are widely available 
in both private and public health facilities; over 90 % of 
Kinshasa’s health facilities supplying anti-malarial medi-
cation also have malaria diagnostics available [29].
The Congolese public healthcare system is formed 
around 516 health zones, with a total of 393 reference 
hospitals, and 8266 lower-level health facilities [26]. 
There is no public insurance or remuneration system, 
and healthcare costs are usually ‘out-of-pocket’ expenses 
paid by patients. Malaria transmission is high and stable 
in most of the country [3]. Malaria policy in DR Congo is 
coordinated by the National Malaria Control Programme 
(NMCP).
Data collection and analysis
Data were collected qualitatively by conducting semi-
structured in-depth interviews with a purposeful sam-
ple of health professionals in Kinshasa. A total of 11 
interviews were conducted with: (1) three nurses from 
a public hospital in Kinshasa; (2) three local malaria 
researchers; (3) four medical specialists connected to the 
local academic hospital (an entomologist, a paediatrician, 
a tropical medicine specialist, an internist); and, (4) one 
NMCP representative.
Interviews were conducted face-to-face, and were 
recorded with consent of each interviewee. These record-
ings were supplemented with auxiliary notes made 
during the interview. Concepts of adoption theory [30] 
and behaviour change theory [31] were used to inspire 
focal topics for investigation in data collection. Adoption 
theory allowed for assessing technology specific attrib-
utes of the semi-quantitative pfHRP2 device. Behaviour 
change theory enabled approaching the adoption deci-
sion from an intrinsic, personal point of view. With some 
respondents, not all concepts were discussed since they 
were not relevant to their area of expertise. Prior to each 
interview, respondents were given an information sheet, 
which provided an explanation of the semi-quantitative 
pfHRP2 device including a schematic visualization of its 
proposed position in the diagnostic work-up. Informa-
tion sheets were available in both French and English. 
Two of the interviews were held in English and the other 
nine in French. The French interviews were conducted 
with assistance from a professional translator experi-
enced with healthcare projects. The translator was thor-
oughly lectured about the project, interview questions 
were reversely translated and a practice interview was 
held to minimize the interpretative bias. After the inter-
views, translator and researcher jointly made transcripts 
for each interview. These transcripts were then line-
to-line coded by the researcher using the theory-driven 
concepts. These focal concepts were complemented by 
taking into account insights that emerged from the inter-
views, creating new codes. Subsequently, pieces of text 
with similar content were grouped together and concepts 
with higher levels of abstraction were formed by a pro-
cess of induction. In this way, both contrasting explana-
tions and recurring themes were captured from data.
Results
Four key contributing factors were identified in the 
interviews with Congolese health professionals: (1) the 
semi-quantitative pfHRP2 device is perceived as an 
intervention with potential to improve management of 
children with febrile illness; (2) the device is considered 
to have limited compatibility with equipment and com-
petences of Congolese practitioners, especially of those 
active in rural settings; (3) a formal training programme 
is crucial for correct application and interpretation of the 
semi-quantitative pfHRP2 device; and, (4) credible evi-
dence provided to practitioners, but supported by health 
authorities, would establish confidence in the device. 
These key factors are now presented in more detail, with 
supporting quotes to illustrate or exemplify findings.
Perceived advantage of the semi‑quantitative pfHRP2 
device over current febrile illness diagnostic practices
The problem of distinguishing children who are ill 
because of malaria from children with a non-malaria 
febrile illness and coincidental parasites in their blood 
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was recognized by the respondents. Due to the current 
lack of a tool to make this distinction, the prospective 
semi-quantitative pfHRP2 device was considered a wel-
come addition to their clinical equipment. This position 
was exemplified by respondent 6:
“When immune children are sick and tested for 
malaria, they will test positive. But they may have 
another type of disease. It would be good to have 
a rapid test for this. Very many people will get the 
clinical diagnosis of malaria but are in fact sick with 
another disease.”
Respondents mentioned three practices which they 
know are currently employed to deal with the possibility 
of a co-existing non-malarial febrile illness after malaria 
is diagnostically detected. The first is to scrutinize each 
febrile patient for symptoms specific to a febrile disease 
prevalent in the area, and base treatment on this hypo-
thetical judgment. However, respondents consider this 
symptomatic search for non-malarial febrile illnesses as 
impractical since most febrile symptoms are not specific 
to one disease. As an alternative to this method, the pre-
scription of anti-malarial medication to all severe febrile 
patients whilst initially neglecting the possibility of a 
co-existing alternative febrile illness was proposed. This 
approach was also considered inappropriate for emer-
gency management since the possibly life-threatening 
non-malarial febrile illness would not be restrained in 
these cases. The third suggested option is to always sup-
plement anti-malarial medication with antibiotics. This 
approach was, however, judged as disadvantageous since 
scarce medication may be wasted.
Throughout the interviews it was repeatedly empha-
sized that availability of a semi-quantitative pfHRP2 
device would open up a fourth option. The addition of 
an extra diagnostic step to indicate the likeliness of a 
co-existing febrile illness after malaria is detected would 
allow health practitioners to improve prescription of 
prompt and suitable medication with more confidence. 
Respondent 4, for example, voiced this appraisal:
“To me a test to show that the illness is caused by 
malaria would be a huge improvement. Because 
with this rapid test you would have evidence-based 
back-up […]. It should then be a very simple test that 
can be used in the field”.
Respondent 1 complemented this by stating that:
“With such a diagnostic, we can treat patients for 
other diseases than malaria, [diseases] in which we 
now lose time because we can only treat symptoms 
while we do not know what it is.”
Since the semi-quantitative pfHRP2 device is being 
developed as a follow-up step in the diagnostic work-up, 
its application would inevitably imply increased clinical 
costs per febrile illness episode. Respondents indicated 
that this could be a barrier to adoption. However, when 
effectiveness is proven by either reduced mortality or 
more appropriately targeted treatment, willingness to pay 
is expected to increase. Additionally, inclusion in a sub-
sidy programme, as is currently the case with RDT in DR 
Congo, was put forward as an effective way of overcom-
ing the financial barrier to adoption by reducing costs:
“RDTs in the country are now subsidized. They are 
free in the public sector. So this test should also be 
free or really, really cheap. A commercial price 
would probably be too expensive. But if you have 
shown that your test really helps, then people are 
willing to pay” (Respondent 4).
Perceived compatibility semi‑quantitative pfHRP2 device 
with current febrile illness management
To effectively incorporate the semi-quantitative pfHRP2 
device into febrile illness management, practitioners 
must have the ability to interpret the test results and 
act accordingly. Evidence that this cannot be assumed 
emerged in the form of three compatibility-related adop-
tion barriers.
First, it came to light that practitioners regularly lack 
awareness of the disease range in their organizations’ 
locality, and that fever is still equated with malaria. They 
lack proficiency to deal with the possibility of an alterna-
tive febrile illness. Respondent 4 explained that
“….when the illness is something else [not malaria], 
they are not prepared for that. They [physicians] are 
not trained to manage these cases. You would expect 
that they are trained to look for signs of other dis-
eases in the case of a negative test, but they are not”.
This problem was not associated with well-educated 
healthcare professionals who are usually clustered in 
and around urban areas. Rather, respondents primar-
ily pointed to practitioners in rural areas of DR Congo, 
since:
“Given the dimensions and size of Congo, and with 
all problems here including the war, competent peo-
ple do not like travelling to the inner country. They 
prefer living in the city. Many of the practitioners liv-
ing in small towns have no experience with diagnos-
tics. We should not bring sophisticated techniques to 
health workers in the inland; because they are not 
competent” (Respondent 5).
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The second barrier concerns the possibility to follow-
up on a negative test result of the semi-quantitative 
pfHRP2 device. Respondents mentioned that Congolese 
hospitals regularly lack tools to identify both malaria and 
non-malarial febrile illnesses. Respondent 3, for example, 
attested that
“In case of illness, the nurses will use some clinical 
signs and they can give children drugs to repress 
fever and some antibiotics. Because there are often 
no tests available to discover which disease may join 
malaria”.
When there is no practice available to conduct a suit-
able follow-up diagnostic work-up, a negative semi-quan-
titative pfHRP2 test result would be an empty step within 
the process. Such a result would merely present malaria 
as an unlikely cause of the severe febrile illness, but the 
actual cause would remain unidentified and suitable 
treatment would remain abstruse.
Third, a regular stock-out of appropriate medication 
was considered an important obstruction to adopt the 
semi-quantitative pfHRP2 device. Respondent 3 evinced 
this with observations made in Bolenge town:
[Respondent describes a fever epidemic where, many 
children tested positive for malaria]. “And the result 
was that 80 children were suffering from malaria or 
another fever. But there were no more drugs to pro-
vide; all were finished.”
Whereas the unavailability of a diagnostic can be 
replaced by switching to presumptive diagnosis, alter-
natives for medication stock-out hardly exist. The only 
suggested options were referring the patient to another 
facility or acquiring medication in a private drug shop. 
The latter case was perceived unattractive since in these 
situations prices can increase ten-fold according to one 
respondent. Again, the problem of diagnostic and medi-
cation stock-out was mainly associated with isolated 
rural areas.
Application and interpretation of the semi‑quantitative 
pfHRP2 device
The semi-quantitative pfHRP2 device will be developed 
as a rapid, point-of-care test design using a drop of blood 
on an indicator strip (lateral flow design) whereupon the 
plasma pfHRP2 level will be displayed on a read-out. In 
the hospitals under study, practitioners conveyed that 
they are familiar with similar tests, such as lateral flow 
format RDT. They declared that this familiarity brought 
them to perceive themselves capable of rapidly learning 
its application. It was stressed that a practical training 
session is nonetheless required every time a new product 
is introduced and the semi-quantitative pfHRP2 device 
would not represent an exception.
“An introduction programme should be similar as 
what was done with the RDT. So when there is a 
new test, the first thing is to have a practical train-
ing. Someone has to show the specific techniques and 
how to use the product” (Respondent 11).
In contrast to the practical application, respondents did 
anticipate complications regarding correct interpreta-
tion of test outcomes. Whereas conventional diagnostic 
devices usually indicate presence of an illness, the semi-
quantitative pfHRP2 device will provide more nuanced 
information on the probability of the underlying cause of 
illness. Here, a more elaborate and in-depth training pro-
gramme was thought to be required, as was exemplified 
by respondent 2:
“An interpretative training would be more difficult 
with this new test than with the RDT because they 
would have to understand what could be the differ-
ent stages of the test and what exactly happens in 
each of these stages”.
It was suggested that interpretative complexity of 
the test results could be further reduced by prac-
ticing how to respond to each possible scenario of 
test-outcomes: “[…] in the training programme they 
should also include projects on how to interpret the 
results; what to do in case of a positive and in case of 
a negative diagnosis” (Respondent 4).
Finally, the importance of a clear definition of the tar-
get patient population was deemed crucial to establish 
understanding in the semi-quantitative pfHRP2 device.
Evidence provision and experimentation 
with semi‑quantitative pfHRP2 device
Respondents indicated that their practices are largely 
dependent on healthcare policy recommendations. Inclu-
sion of the semi-quantitative pfHRP2 device in treatment 
guidelines from a governmental health authority would 
be a strong re-inforcement towards adoption. Govern-
mental endorsement, such as the NMCP, was deemed 
crucial to acceptability. Congolese practitioners would 
not perceive evidence provided by other parties, such as 
manufacturers, as reliable.
“People from the Ministry would have to confirm 
your product, because if you approach them by 
yourself, people will not believe you. But when they 
see a member of the Health Ministry joining you, 
then you have the credibility” (Respondent 2).
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One health practitioner expressed that adherence to 
principles of good governance within governmental 
authorities is not obvious in DR Congo, and that conflict-
ing interests could affect objective endorsement by mem-
bers of the NMCP.
As well as the importance of national guidance, 
respondents emphasized the relevance of taking local 
interpretations into account. For example, respondents 
knew of various instances in which practitioners may 
decide to deviate from national guidelines due to a dif-
fering personal judgment. Evidence that the semi-quan-
titative pfHRP2 device is effective and reliable should 
therefore not solely be presented to the NMCP, but also 
to practitioners personally:
“You would need to have the result of clinical trials, 
which are relevant for both the NMCP and the doc-
tors. Because also doctors need to learn about the 
accuracy” (Respondent 6).
It was further emphasized that, in order to be per-
ceived as credible, presented evidence should have been 
obtained from the same respective area as where it is 
presented, since locally obtained evidence is perceived 
to be more trustworthy than evidence from elsewhere. 
Conditions such as disease prevalence and intensity dif-
fer per area and evidence from another country or even 
another locality within DR Congo would not be regarded 
as credible.
“I insist that all new products must be tested under 
local conditions. Also within the country we have 
different circumstances and different cultures” 
(Respondent 3).
This significance for locally collected evidence, com-
bined with a de facto accreditation by the national gov-
ernment, leads to intense vertical learning but not so 
much to knowledge transfer between hospitals.
It was furthermore put forward that enabling health 
practitioners to experiment with the semi-quantitative 
pfHRP2 device would increase their willingness to adopt.
“We should have time to experiment with the tech-
niques and the material of the new test […] After 
that we have to practice in the hospital, and by doing 
so, experience is raised and the practice becomes 
more and more fixed” (Respondent 11).
Whilst practitioners are usually sceptical of new prac-
tices, a try-out period would increase their confidence in 
the device’s effectiveness. Positive outcomes are valued 
during such trial period since a respondent stated that 
attitudes towards the device would be influenced nega-
tively if the test did not work well.
Discussion
The paradigm shift towards parasite-based diagnosis 
of malaria has enhanced recognition of the importance 
of integrating malaria management with management 
of other febrile illnesses, as also propagated in previous 
studies from Ghana and Zanzibar [32, 33]. Usage of the 
semi-quantitative pfHRP2 device could be an additional 
step in that direction with particular relevance to the 
refinement of management in severe disease. A more 
nuanced insight into the cause of a severe febrile illness 
episode, as obtainable by this prospective device would 
enable practitioners to further improve management of 
both malaria and non-malarial febrile illnesses. Severe 
febrile illness caused by either malaria or invasive bac-
terial infections or by a combination of these poses an 
important problem for the treating health practitioner. 
As reviewed by Church and Maitland, one-third of all 
deaths from severe malaria occur in children with bac-
terial co-infection and the main pathogens involved are 
enteric gram-negative organisms and non-typhoid sal-
monellae [34]. In addition to low plasma pfHRP2, both 
recent malaria (defined as whole blood pfHRP2-based 
RDT positive, but malaria slide negative) and hyper-
parasitaemia have been shown to be a risk factors for 
concomitant bacteraemia complicating malaria [9, 13]. 
The benefit of an additional simple test to distinguish 
better between the different syndromes would be a core 
advantage over other currently available febrile illness 
management algorithms. This was recognized by Congo-
lese practitioners given that respondents explicitly men-
tioned that the semi-quantitative pfHRP2 device would 
be a welcome addition to their clinical equipment. Even 
so, they are neither likely to initiate adoption themselves 
nor be open to adoption when approached by a commer-
cial manufacturer. Rather, support of the Health Minis-
try implicit in treatment guidelines was emphasized as 
a requisite for embracing the semi-quantitative pfHRP2 
device. Recommendation of the device by governmental 
authorities such as the NMCP is perceived as proving 
reliability whilst lack of support reduces both accessibil-
ity and visibility. This perceived significance for central 
coordination is noteworthy, since a lack of trust in the 
national public healthcare system was also voiced.
A second finding is that evidence of the effectiveness 
of the semi-quantitative pfHRP2 device should be pre-
sented to practitioners personally rather than solely to 
the NMCP. Even though inclusion in NMCP guidelines 
implies that a test is useful, practitioners also exercise a 
degree of autonomy and personal judgment. The more 
convinced they are that the semi-quantitative pfHRP2 
device bears the purported clinical benefits, the more will-
ing they will be to adopt it. A further finding of interest 
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is the preference for local demonstration of the advan-
tages of a novel tool. Practitioners are sceptical towards 
evidence gathered in other healthcare sites than those in 
their own region. It was, for example, explicitly mentioned 
that evidence of effectiveness from Zambia would be per-
ceived close to worthless in DR Congo, but also within 
the country evidence should, according to respondents, 
be collected and distributed locally. In terms of evidence 
gathering and knowledge production, this study contrasts 
with findings from Chandler in Ghana, where it was pro-
posed that social learning processes between practition-
ers are essential for reaching the full potential of RDT 
[35]. In the case of the semi-quantitative pfHRP2 device 
in DR Congo, respondents expected learning processes to 
be more top–down and centrally coordinated instead of 
horizontal. The importance of evidence being locally pro-
duced and distributed is not yet represented in published 
literature. It is important to realize that recognition of the 
usefulness or importance of an additional diagnosis tool 
does not imply necessarily that the test will change prac-
titioners’ decision-making. Different studies have shown 
that adherence to point-of-care malaria tests often are 
considerably low, even when training sessions are organ-
ized to emphasize the importance of appropriate follow-
up behaviour [36, 37]. This problem is especially related 
to malaria overdiagnosis where practitioners regularly 
prescribe malaria treatment despite negative diagnosis 
[36]. The culture of limited consideration of negative test 
results could also be a threat to reaching full potential of 
the semi-quantitative pfHRP2 device.
Thirdly, respondents deemed themselves capable of 
learning quickly how to utilize the device. Their experi-
ence with similar test designs, such as RDT, is expected 
to accelerate their attainment of the required technical 
skills. Nonetheless, respondents emphasized the impor-
tance of a formal training programme to become familiar 
with the practical appliance of the device and its pro-
posed position in the broader context of febrile illness 
management. The significance of formal training ses-
sions, including provision of information on appropriate 
follow-up of negative cases, has been stressed extensively 
in the context of implementation of RDT [35, 38]. These 
adoption factors also seem to be relevant in the case of 
the semi-quantitative pfHRP2 device. Furthermore, one 
study emphasized the importance of technical super-
vision, consistent training messages and a continuing 
quality-control system to build and sustain confidence 
in RDT in the Solomon Islands [38]. The current study 
is consistent with these findings, but extends the list by 
stressing the significance role of governmental authori-
ties in providing training messages and the possibility 
for practitioners to try out the semi-quantitative pfHRP2 
device prior to adoption.
Despite the recognized potential of the semi-quantita-
tive pfHRP2 device in the Congolese healthcare system, 
two major adoption barriers emerged from this study. 
The first concerns the extra costs associated with adop-
tion. Since public insurance and reimbursement systems 
are non-existent in DR Congo, healthcare expenses are 
usually ‘out-of-pocket’ payments by patients, and prac-
titioners are directly dependent on these payments for 
their own income. Due to this payment system, offer-
ing the semi-quantitative pfHRP2 device at a commer-
cial price was considered likely to hamper adoption. 
Respondents were cautious in offering concrete price 
indications as ‘willingness to pay’ is largely determined 
by specifications such as test specificity and sensitivity 
and also depends on the price of related diagnostic tools 
and follow-up medication. A previous study in Tanzania 
has shown that cost-effectiveness of malaria diagnostics 
depends on consistent adherence to test results and also 
correlates with transmission rates [37]. A suitable follow-
up for the current study would be cost-effectiveness and 
‘willingness to pay’ studies taking into account such ele-
ments for the semi-quantitative pfHRP2 device.
The second barrier relates to the compatibility of the semi-
quantitative pfHRP2 device with current febrile illness man-
agement practices. A prerequisite for usefulness of the device 
is that its users have relevant clinical resources and personal 
capabilities to manage the device in this broader febrile dis-
ease context. This is expected to be problematic in DR Congo 
since knowledge of the local ‘illness range’ regularly appears 
absent, and the additional information obtained using the 
semi-quantitative pfHRP2 device is expected to be complex. 
Moreover, availability of diagnostics to detect non-malarial 
febrile illnesses is mostly absent in the country, as well as 
access to appropriate medication. This would compromise 
the benefit of the semi-quantitative pfHRP2 device for the 
diagnostic work-up. These challenges are primarily associated 
with isolated rural areas in the Congolese inland. Especially 
in the rural settings, there is a consistent lack of diagnostic 
and medical resources whilst those localities also suffer from 
a shortage of competent and educated practitioners. In urban 
areas, resources are more clustered and there is usually a pos-
sibility to refer a patient to another facility with more exper-
tise and clinical resources [2]. The relevance of compatibility 
issues to rural hospitals compared to urban equivalents was 
pointed out by respondents in the current research.
Some limitations of the study must be taken in considera-
tion. Firstly, the study was purely qualitative in nature and 
thus cannot provide insight into the degree to which adop-
tion factors are relevant. Secondly, even though efforts were 
made to minimize interpretative bias, it is inevitable that 
certain nuances are lost by intervention of the translator. An 
important limitation with regard to external validity relates 
to the fact that the research was conducted in different health 
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centres in one city, Kinshasa. This may imply limited gener-
alizability of their statements and visions to the whole coun-
try, which accommodates many cultures and local factors in 
a large territory. However, a great number of respondents 
indicated that they have worked in other (rural) localities and 
therefore this could make their assessment more balanced. 
Conducting the study within a broader sample of respond-
ents in different hospitals and inclusion of rural hospitals 
would be an appropriate follow-up step for this research.
Conclusion
Respondents perceived the emerging semi-quantitative 
pfHRP2 device as a welcome addition to practitioners’ 
clinical equipment. The device could improve current 
diagnostic work-up of severe febrile illness that might 
consequently improve treatment choices. However, 
despite this recognized theoretical potential, implemen-
tation of this prospective device in DR Congo is likely 
to encounter several hurdles, in part related to required 
financial resources but also to challenges associated with 
the broader context of febrile illness management.
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